Your session is about to expire
← Back to Search
Apixaban 2.5 milligram for Inflammatory Bowel Disease (EXPAND Trial)
EXPAND Trial Summary
This trial will study whether a medication can help prevent blood clots in people with inflammatory bowel disease who have had surgery.
EXPAND Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEXPAND Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EXPAND Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this clinical experiment pioneering in its field?
"Apixaban 2.5 milligram is currently being trialled in 34 nations, across 379 cities. This drug first entered clinical trials in 2015 when Bristol-Myers Squibb conducted a Phase 4 assessment with 4012 patients as part of the study; since then, 47 active studies have been undertaken and 282 completed thus far."
What is the size of the patient cohort in this medical experiment?
"Affirmative. The clinicaltrials.gov website reveals that this medical trial, which went live on September 1st 2021, is still actively recruiting participants. Sixty patients need to be enrolled from two distinct sites."
Are there still openings in this research experiment for participants?
"As per clinicaltrials.gov, this medical trial is still in search of volunteers. The initial post was made on September 1st 2021 and the last update occured on August 26th 2022."
Share this study with friends
Copy Link
Messenger